CTOs on the Move

10X Genomics

www.10xgenomics.com

 
10x Genomics meets the critical need for long range, structural and cellular information, with an innovative system that transforms short-read sequencing technologies. Our Chromium™ System supports comprehensive genomics and high-throughput single cell transcriptomics. It enables researchers to discover previously inaccessible genomic information at unprecedented scale, including phased structural variants, phased single nucleotide variants, and dynamic gene expression of individual cells—while leveraging their existing sequencing systems and workflows.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.10xgenomics.com
  • 7068 Koll Center Parkway Suite 401
    Pleasanton, CA USA 94566
  • Phone: 925.401.7300

Executives

Name Title Contact Details
Jason Gao
 Head of Information Security Profile

Funding

10X Genomics raised $55M on 03/17/2016
10X Genomics raised $75M on 04/26/2018
10X Genomics raised $50M on 04/26/2018
10X Genomics raised $35M on 01/07/2019

Similar Companies

Mesa Biotech

Accurate. Accessible. Actionable. Simplifying PCR, transforming healthcare.

Sonitus Medical Inc.

Sonitus Medical Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Premera

Premera is a Mountlake Terrace, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novaseek Research

Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!

Imara

Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.